Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 478 participants.

Also called NCT01890434

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 478 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01890434
  • EudraCT 2013-000066-11
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Singapore (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01890434. Allocation not applicable; no masking; primary purpose diagnostic. Start 2013-08-26 (actual); primary completion 2016-08-06 (actual). Results posted on 2018-05-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Acronym
GadaCAD 2
Intervention (Drug)
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01890434
Content hash
ea1d50d2cfbd0b2ba73241f0738f8b3cd658be65ed8a651debeb70042ad598ed